Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study

Published:2022-02 Issue:4 Volume:10 Page:205-205
ISSN:2305-5839
Container-title:Annals of Translational Medicine
language:
Short-container-title:Ann Transl Med

Author:

Yan Ying,Li Huimin,Wu Shusheng,Wang Gang,Luo Huiqin,Niu Jiayu,Cao Lulu,Hu Xiaoxiu,Xu Huijun,Jia Wei,Sun Yubei,Yao Yiwei,Chen Wenju,Ke Lihong,Hu Bing,Ji Chushu,Sun Yancai,Chen Jian,Li Mengge,He Yifu

Publisher

AME Publishing Company

Subject

General Medicine

Link

https://atm.amegroups.com/article/download/90291/pdf

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Low-Dose Apatinib Combined with Chemotherapy as Second-Line Treatment for Advanced Gastric Cancer: A Meta-Analysis;Chemotherapy;2023-06-20

2. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting;Frontiers in Oncology;2023-06-16

3. Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial;Frontiers in Oncology;2023-04-24

4. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer;Disease Markers;2022-09-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP